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Background: Antidepressant prescribing continues to rise. Increased long-term prescribing and higher doses are
contributing to current growth; however, patient factors associated with the use of higher doses remain unknown.
This study’s aim was to investigate patient factors associated with selective serotonin re-uptake inhibitor (SSRI)
prescribed daily dose for depression treatment in general practice.
Methods: A stratified sample of low to high prescribing practices were selected. Routine individual patient-level
data were extracted one practice at a time: September 2009 to January 2011. Patients included were ≥18 years, and
prescribed an SSRI for depression. Logistic regression analysis was undertaken to assess individual predictor variables
on SSRI daily dose by standard therapeutic dose versus higher dose, as SSRIs demonstrate flat dose response curves
for depression treatment. Predictor variables included: age, gender, deprivation, co-morbidity, smoking status,
being prescribed the same SSRI for ≥2 years, and patients’ general practice. For a subgroup of patients a second
sub-group analysis included long-term benzodiazepine and/or z-hypnotic (B&Z) as a predictor variable.
Results: Inter-practice SSRI prescribing varied significantly; practice point prevalence ranged from 2.5% (94/3697) to
11.9% (359/3007) of the practice population ≥18 years old; median 7.3% (250/3421) (χ2 = 2277.2, df = 10, p < 0.001).
Overall point prevalence was 6.3% (3518/52575), with 5.8% (3066/52575) prescribed SSRIs for depression of whom
84.7% (2596/3066) had data for regression analysis. Higher SSRI doses were significantly associated with, in
descending order of magnitude, individual practice attended, being prescribed the same SSRI for ≥2 years (Odds
Ratio (OR) 1.80, 95% CI 1.49 to 2.17, p < 0.001) and living in a more deprived area (OR 1.55, 95% CI 1.11 to 2.16,
p = 0.009). Higher SSRI doses in the B&Z subgroup were significantly associated with individual practice attended,
being prescribed a long-term B&Z (OR 2.05 95% CI 1.47 to 2.86, p < 0.001) and being prescribed the same SSRI
for ≥2 years (OR 1.94, 95% CI 1.53 to 2.47, p < 0.001).
Conclusion: Higher SSRI doses for depression were associated with practice attended and being prescribed the
same antidepressant for ≥2 years. As long-term antidepressant use increases, the use of higher doses may further
contribute to prescribing growth.
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Antidepressant prescribing has increased substantially
across Europe, USA and Australia over the last 40 years
[1-5] and has attracted much discussion, debate and
concern over the last 40 years [1,6,7]. In Scotland it was
estimated that 11.3% of the adult population were pre-
scribed antidepressants in 2010/11 [8]. Concerns over
the number of people receiving antidepressants and in-
creased prescribing led the Scottish Government in 2007
to set Health improvement, Efficacy, governance, Access
to services and Treatment (HEAT) targets to reduce pre-
scribing. These targets were not met due to poor target
design and limited knowledge about antidepressant pre-
scribing and use [9].
As elsewhere, the majority of antidepressants are pre-
scribed by general practitioners (GPs) for the treatment
of depression [10-12] with the rest prescribed for other
conditions [13,14]. Although prescribing continues to
increase, there is no clear corresponding increase in
depression incidence or prevalence [15,16]. Increased
prescribing has so far been explained at national and
local levels by a combination of factors: increased selec-
tive serotonin re-uptake inhibitor (SSRI) use [2,5], in-
creased long-term prescribing [16] and the probable use
of higher doses [12,17]. SSRIs are of particular interest
as they account for 53% of all antidepressant prescrip-
tions and 67% of all antidepressant defined daily doses
(DDDs) prescribed [8]. DDDs are units of measurement
defined by the World Health Organization as ‘the as-
sumed average maintenance dose per day for a drug
used for its main indication in adults’. DDDs do not
necessarily reflect the recommended or prescribed daily
dose but allow a convenient method to compare pre-
scribing volumes between organisations [18].
There are large variations in prescribing between prac-
tices which are influenced by practice level characteristics:
list size, number of GPs, proportion of female GPs, and
population factors including age, gender, deprivation and
long-term illness [19]. Depression prevalence is influenced
by similar factors with chronic diseases such as diabetes,
coronary heart disease, stroke, hypertension, asthma or
chronic obstructive pulmonary disease (COPD) increasing
individuals’ depression risk [20,21]. Smoking has also been
reported to have a bidirectional relationship with depres-
sion and may influence antidepressant response [22]. We
were also interested in the influence of benzodiazepines
and/or z-hypnotics (B&Zs) due to their negative effects on
depression and weak associations with antidepressant
prescribing [23-25]. The majority of published studies
exploring factors relating to prescribing volumes lack
patient-level information, such as antidepressant indica-
tion and dose [2,5,15-17,19].
Although antidepressant doses are one factor which
may contribute to current growth and prescribingvariations, it remains unclear to what extent individual
patient factors influence daily dose. A better understan-
ding of these may enable the development of strategies
supporting more appropriate antidepressant prescribing.
Therefore, the aim of this study was to investigate
patient-level factors independently associated with SSRI
prescribed daily dose for the treatment of depression in
general practice.
Methods
Setting and design
This cross sectional study is a secondary analysis of rou-
tinely available data from a stratified sample of low to
high volume antidepressant prescribing general practices
in the NHS Greater Glasgow and Clyde (NHSGG&C).
NHSGG&C provides healthcare services for a diverse
population of approximately 1.2 million people across a
varied urban area containing 269 general practices, and
in response to the HEAT target committed to further
understanding current practice and supporting appro-
priate antidepressant use [26].
The 269 practices were ranked low to high antide-
pressant prescribers, by defined daily doses (DDDs)/
1000 patients from Prescribing and Information System
for Scotland (PRISMS) for year to March 2009. PRISMS
is a web-based application providing information for all
community dispensed prescriptions, and can be interro-
gated to provide practice level reports. Ranked practices
were then categorised as low (practice 1 to 89: 8,076 to
25,657 DDDs/1000 patients), medium (practice 90 to
179: 25,666 to 34,872 DDDs/1000 patients) and high
(practice 180 to 269: 34,886 to 65,409 DDDs/1000 pa-
tients) prescribers; practices were recruited from each
category with varying characteristics known to influence
antidepressant volumes: practice size and deprivation
code [19]. Other factors such as patient ethnicity, GP
training and country of birth, and practice rurality al-
though known to influence antidepressant volumes [19]
were not included due to unreliable data quality and
NHSGG&C serving an urban area.
Practices within each prescribing category with a mix-
ture of characteristics were invited to participate in HEAT
target service evaluation work through a third party; their
local Community Health and Care Partnership (CHCP)
prescribing support team. In 2009 NHSGG&C consisted
of 10 CHCPs serving populations with varying levels of
deprivation. CHCP prescribing support teams serving
areas of low to high deprivation were asked to select and
approach potential practices for participation in HEAT
target service evaluation work. Six CHCPs supported
practice recruitment with 12 practices agreeing to par-
ticipate. Ethical opinion was sought from the West of
Scotland Research Ethics Service on the use of anony-
mised patient-level data for this study; however, the ethics
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not requiring ethics service approval, although Caldicott
Gaurdian approval would be required [27]. Eleven of the
12 practices gave Caldicott Guardian approval to use
anonymised patient-level data (Table 1); one medium pre-
scribing practice declined approval to use anonymised
data and were excluded. All practices were ‘paper-light’,
recording clinical information electronically for >5 years
on individual practices’ General Practice Administration
System Scotland (GPASS). GPASS was the most widely
used general practice system in NHSGG&C at this time.
The 11 study practices' patient demographics are simi-
lar to 47% (481/1014) of Scottish general practices by
urban setting, proportion of patients aged 15 to 74 years
old and patient-level SIMD deprivation quintiles. These
481 practices serve 55% (3/5.5 million people) of the
Scottish population with 202 of these practices being
with in NHSGG&C and serving 1 million people [28].
Identification of study participants
A single cross sectional data extraction was made for each
practice between September 2009 and January 2011. A
prescribing support pharmacist used electronic data
extraction tools specifically designed and piloted to iden-
tify all patients prescribed an SSRI within the previous
3 months, and whether the same patients were prescribed
the same SSRI for ≥2 years from individual practices’
GPASS. As current guidelines recommend up to 2 years
antidepressant treatment for those at higher risk of relapse
[29-31], this was considered an appropriate measure of
long-term antidepressant use. Patients were included ifTable 1 Practice characteristics
Practice *ADM volume
DDDs/1000
patients (category)
SSRI volume
DDDs/1000
patients (%)†
Total practice
population ≥18 years
(female:male)
Num
GPs
1 9576 (L) 6933 (72.4) 3697 (1072:2625)
2 18295 (L) 12630 (69.0) 9806 (5327:4479)
3 20752 (L) 14600 (70.4) 6736 (3601:3135)
4 28169 (M) 19714 (70.0) 4324 (2262:2062)
5 29894 (M) 20860 (69.8) 5741 (2964:2777)
6 31038 (M) 20967 (67.6) 3421 (1657:1764)
7 35490 (H) 25448 (71.7) 3956 (2005:1951)
8 41917 (H) 26710 (63.7) 5010 (2493:2517)
9 44637 (H) 30344 (68.0) 3121 (1653:1468)
10 49393 (H) 31885 (64.6) 3756 (1888:1868)
11 65409 (H) 46309 (70.8) 3007 (1550:1457)
*From Prescribing Information Systems Scotland (PRISMS) data year to March 2009.
ADM: antidepressant medicines. DDDs: defined daily doses.
Category: Ranked as L – Low, M – Medium and H – High prescribers from PRISMS.
SSRI: selective serotonin re-uptake inhibitors. †% of total antidepressant DDDs/1000
SIMD: Scottish Index of Multiple Deprivation, ‡categorise by practice postcode quinthey were ≥18 years old and prescribed an SSRI to treat
depression, including mixed depression anxiety.
The tools simultaneously gathered individuals’ anti-
depressant prescription information, age, gender, co-
morbidities (Read Codes for diabetes, coronary heart
disease, stroke, hypertension, asthma or COPD), smo-
king status and Scottish Index of Multiple Deprivation
(SIMD) code derived from each patient’s residential
postcode [32]. Co-morbidities and smoking status infor-
mation was readily available, having been recorded and
monitored as part of the general practice General Medical
Services contract; Quality Outcomes Framework; details
of Read Codes see Additional file 1: Appendix 1.
We were aware of limitations with using depression
Read Codes as a marker of antidepressant indication as
there is no contractual obligation for GPs to code patients
receiving treatment for depression. Read Codes are a
standard hierarchical classification system for recording
patient medical information in UK primary care [33]. Pre-
vious studies highlighted a lack of documented diagnosis
[10,34], and audits in five NHSGG&C practices demon-
strated <50% of patients receiving antidepressant treat-
ment for depression were coded for depression. Therefore
the primary indication was identified using a combination
of electronic GPASS Read Codes and patient encounter
information. For a small minority of patients electronic re-
cords of antidepressant indications were not available from
GPASS therefore individuals’ clinical notes were manually
checked for antidepressant indication at the date of initi-
ation by NHS staff before the data set was anonymised.
Patients with no clear indication were recorded as indica-
tion unknown and excluded.ber of ‡SIMD
quintile
Training
practice
% patient prescribed
an SSRI (number of
patients/practice
population ≥18 years)
2 4 No 2.5% (94/3697)
5 5 Yes 3.4% (337/9806)
6 1 Yes 5.2% (353/6736)
5 4 Yes 6.0% (261/4324)
4 5 No 8.5% (487/5741)
3 4 No 7.3% (250/3421)
3 2 No 7.6% (299/3956)
6 5 Yes 9.0% (451/5010)
3 5 No 8.4% (262/3121)
4 4 Yes 9.7% (365/3756)
2 5 Yes 11.9% (359/3007)
patients.
tile 1 (least deprived) to 5 (most deprived).
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z-hypnotic (B&Z) long-term prescribing data were sim-
ultaneously collected, as previous practice level studies
indicate an association between antidepressant and B&Z
prescriptions [25,35]. However, data was not collected
from 4 practices due to limited staff and time resources.
The 7 practices were comparable by urban setting, pro-
portion of patients aged 15 to 74 years old and patient-
level SIMD deprivation quintiles to 251 Scottish prac-
tices serving 1.5 million people, 124 of these practices
being within NHSGG&C. Long-term use was defined as
≥8 weeks continuous use as the majority of B&Zs are li-
censed for short-term use of 2-4 weeks [13].
Data operationalisation and statistical analysis
Explanatory variables were included in a statistical mo-
del which we hypothised from the literature would in-
fluence SSRI prescribed daily dose, and are known to be
associated with depression and variations in general
practice antidepressant prescribing [19-22,25,35]. These
were individuals’ age, gender, residential SIMD quintile,
co-morbidity status, smoking status, being prescribed
the same SSRI for ≥2 years, and their general practice.
Co-morbidity was categorised into three options, having
none, one or ≥2 co-morbidities.
The outcome variable of interest was patients’ SSRI pre-
scribed daily dose, expressed as DDDs, as defined by
WHO [18]. For example, a prescribed daily dose of 20 mg
or 30 mg citalopram was recorded as 1 DDD or 1.5 DDDs,
respectively. The statistical distribution of SSRI DDD data
was decidedly ‘non-normal’, and was ‘tooth-like’ with sub-
stantial bimodal peaks observed at DDD equivalents of 1.0
and 2.0. As SSRIs demonstrate a flat dose response curve
for the treatment of depression with 1 DDD representing
a therapeutic dose [18,29-31,36,37], the outcome variable
of prescribed daily dose was dichotomised as a binary out-
come variable of ≤1 or >1 DDD i.e. those with a standard
therapeutic dose versus those with a higher dose. Knowing
that a DDD equal to 2 was not necessarily twice as effec-
tive as a DDD equal to 1, it was decided to adopt a logistic
regression model in preference to an ordinal logistic
model.
A multi-level model was considered to take account of
clustering within practices, however practice level vari-
ables were crude and the number of practices were rela-
tively low limiting the meaningful use of the feature of
clustering within practices in a statistical model. Very lit-
tle work has been published to date on the minimum
number of clusters required for a multi-level model,
however an exploratory analysis done elsewhere sug-
gested there should be at least 10 to 15 clusters [38],
therefore with 11 practices the dataset was on the mar-
gins of what may be a robust approach. As the practices
were not selected at random, and were a stratifiedsample, fitting practice as random effects variable was
ruled out. It was hypothesised that the individual
patient-level factors would be more explanatory of the
variability in SSRI prescribing than of practice level fac-
tors, and that we could retain practice attended as a
fixed effect patient-level variable in a pooled practice
model, provided the heterogeneity of the coefficients of
each explanatory variable was not dramatically different.
To test this we ran a logistic regression model for each
practice in turn and tabulated variable coefficients with
any statistical significance for gender, age, co-morbidities,
smoking status, SIMD code derived from patients’ resi-
dential postcode and the use of the same SSRI for ≥2 years.
We found that practices did not dramatically differ and
proceeded to use the statistical model with practice
attended as a patient-level fixed effect variable using the
pooled patient data from all practices.
Exploratory analysis revealed a curvilinear relationship
with age and prescribed daily dose. Different transforma-
tions for age were undertaken and although they im-
proved model fit, the model failed to meet statistical
assumptions. However by truncating at ≤70 years, these
assumptions were met and this upper age limit was
retained in the model.
The approach taken was one of a full model fitting all
predictor variables we hypothesised from existing evidence
which were known to have an effect on antidepressant
prescribing. We then used backwards stepwise elimination
of variables, in turn, for those which did not achieve a sig-
nificance level of p = 0.05 to explore what effect was
achieved in gaining model parsimony i.e. the best model
‘fit’ with the fewest number of predictor variables. We
pre-specified a low significance level of p = 0.05 as a cut-
off in eliminating variables in turn as the dataset contained
a large number of individuals enabling statistical signifi-
cance to be more easily achieved. We retained variables
greater or equal to p = 0.05 if they improved model fit.
A second logistic regression analysis was also under-
taken for the subgroup of patients from 7 practices with
data on long-term B&Z prescribing. B&Z data were cate-
gorised into a variable with two groups, being prescribed
a B&Z long-term or not.
Data were analysed using Stata 11.2.
Results
Inter-practice SSRI prescribing varied significantly;
practice point prevalence ranged from 2.5% (94/3697)
to 11.9% (359/3007) of the practice population ≥18 years
old; median 7.3% (250/3421) (χ2 = 2277.2, df = 10,
p < 0.001). The SSRI point prevalence over all 11 prac-
tices was 6.3% (3518/52575) of which 67.3% (2369/
3518) were female; 5.8% (3066/52575) of the total prac-
tice population received an SSRI for treatment of de-
pression (Table 2).
Table 2 Antidepressant indication
Number of patients prescribed
an SSRI n = 3518 (%)
Depression/Mixed depression anxiety 3066 (87.2)
Anxiety disorder 305 (8.7)
Bipolar 46 (1.3)
Schizoaffective 38 (1.1)
Personality disorder 10 (0.3)
Unknown 18 (0.5)
Other mental health 15 (0.4)
Other general medical 20 (0.6)
Other mental health: insomnia, eating disorders, etc.
Other general medical: neuropathy, menopausal symptoms, irritable bowel
syndrome, premature ejaculation, etc.
Table 3 Patient demographics and independent variables
n = 2662 Unadjusted odds
ratio (95% CI)
p-value
Mean Age ± SD
(range) years
45 ± 13 (18 to 70) 1.00 (0 .99 to 1.01) 0.85
Male (%) 884 (33.2) 1
Female (%) 1778 (66.8) 1.03 (0.86 to 1.23) 0.734
Deprivation (%)
SIMD quintile 1
(least deprived)
248 (9.3) 1
SIMD quintile 2 322 (12.1) 1.17 (0.80 to 1.72) 0.41
SIMD quintile 3 167 (6.3) 1.67 (1.08 to 2.58) 0.021
SIMD quintile 4 522 (19.6) 1.38 (0.98 to 1.94) 0.068
SIMD quintile 5
(most deprived)
1364 (51.2) 1.55 (1.11 to 2.16) 0.009
SIMD unknown
(not in model)
39 (1.5)
†Co-morbidities (%)
0 1728 (64.9) 1
1 665 (25.0) 1.10 (0.90 to 1.33) 0.356
≥2 269 (10.1) 1.18 (0.90 to 1.54) 0.238
Current Smoking
Status (%)
Non-smoker 1581 (59.4) 1
Smoker 1050 (39.4) 1.13 (0.95 to 1.34) 0.165
Smoking status
unknown
(not in model)
31 (1.2)
SSRI use (%)
ADM for <2 y (%) 1909 (71.7) 1
Same ADM for ≥2 y 753 (28.3) 1.80 (1.49 to 2.17) <0.001
Practice (% practice pop.)
1 82 (2.2) 1
2 265 (2.7) 1.98 (1.09 to 3.57) 0.024
3 242 (3.6) 1.26 (0.68 to 2.35) 0.461
4 191 (4.4) 3.26 (1.77 to 5.99) <0.001
5 372 (6.5) 1.50 (0.84 to 2.69) 0.171
6 201 (5.9) 2.69 (1.47 to 4.94) 0.001
7 224 (5.7) 2.20 (1.21 to 4.01) 0.01
8 322 (6.4) 1.81 (1.01 to 3.24) 0.047
9 181 (5.8) 3.80 (2.06 to 7.01) <0.001
10 302 (8.0) 2.32 (1.29 to 4.18) 0.005
11 280 (9.3) 3.54 (1.96 to 6.38) <0.001
Odds ratio: unadjusted. CI: 95% confidence interval. SD: standard deviation.
SIMD: Scottish Index of Multiple Deprivation. SSRI: selective serotonin
re-uptake inhibitor. ADM: antidepressant medicine.
†Co-morbidities: Individuals had one or more of the following: asthma, COPD,
cardiovascular disease, stroke, diabetes mellitus and/or hypertension.
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≤70 years old than those >70 years (mean ± SD), 1.43 ± 0.69
DDDs versus 1.12 ± 0.51 DDDs (Mann-Whitney U test
p < 0.001). There was no significant difference in SSRI pre-
scribed daily dose by gender within the age groups.
Regression analysis
97.5% (2596/2662) of patients ≤70 years had complete
data for all predictor variables, and were entered into a lo-
gistic regression model (Table 3). We hypothesised an age
gender interaction term would be necessary as women live
longer than their male counterparts and older age is asso-
ciated with lower SSRI doses; however, the interaction
term was not significant, did not improve model fit, and
was left out. All the model assumptions held: there was no
evidence of multi-collinearity (no variables were highly
correlated >0.8), the link test was correctly specified (hatsq
z = 0.90; p = 0.37), and Hosmer and Lemeshow’s good-
ness of fit test failed to achieve significance (Chi-square
(8) = 6.10; p = 0.64). No outliers were excluded for having
disproportionate leverage on the model.
Higher prescribed daily dose was significantly associa-
ted with the following variables in descending order of
magnitude by odds ratios: individual practice attended,
being prescribed the same SSRI for ≥2 years, and living
in a more deprived area (Table 3). There were signifi-
cant differences between doses for those prescribed
SSRIs short-term versus those prescribed the same SSRI
for ≥2 years (Table 4), with significant increases ob-
served for all SSRIs except paroxetine and escitalopram.
Long-term B&Z use
Seven practices had data available for a subsequent ana-
lysis exploring B&Z association with SSRI prescribed
daily dose. 11.8% (190/1610) of the subset were pre-
scribed long-term B&Zs; 1567 (97.3%) had complete
data and were included. In this analysis, we found higher
prescribed daily dose was significantly associated withthe following variables in descending order of magnitude
by odds ratios: individual practice attended, being pre-
scribed long-term B&Z and being prescribed the same
Table 4 Mean daily doses and differences in short-term and long-term (same SSRI ≥2 years) mean doses
ADM <2 years (n = 1909) ADM ≥2 years (n = 753) Difference in
mean dose
(mg) 95% CI
Mann-Whitney
U-test‡
All ADMs (n = 2662)
Number of
ADMs (%)†
Mean dose
(SD) mg
Number of
ADMs (%)†
Mean dose
(SD) mg
Number of
ADMs (%)
Mean dose
(SD) mg
Citalopram 929 (34.9) 25.8 (12.2) 258 (9.7) 31.2 (14.8) 5.4 (3.6 to 7.2) <0.001 1187 (44.6) 27.0 (13.0)
Fluoxetine 753 (28.3) 27.2 (12.0) 316 (11.9) 30.6 (14.0) 3.4 (1.6 to 5.2) <0.001 1069 (40.2) 28.2 (12.7)
Sertraline 147 (5.5) 91.0 (43.7) 76 (2.9) 106.6 (49.2) 15.6 (2.3 to 28.8) 0.019 223 (8.4) 96.3 (46.1)
Paroxetine 35 (1.3) 28.0 (11.8) 67 (2.5) 29.4 (12.7) 1.4 (-3.6 to 6.4) 0.832 102 (3.8) 28.9 (12.3)
Escitalopram 44 (1.7) 15.2 (5.6) 35 (1.3) 15.4 (6.8) 0.2 (-2.6 to 3.0) 0.94 79 (3.0) 15.3 (6.1)
Fluvoxamine 1 (0.0) 1 (0.0) 2 (0.1)
Total 1909 (71.7)† 753 (28.3)† 2662 (100%)
Note: Total mean dose and difference in doses between short-term and long-term use presented as means and SD to aid clarity of actual differences groups.
ADMs: antidepressant medicines. SD: standard deviation.
†: Percentage of total antidepressants prescribed to the 2662 patients.
‡: Dose distribution for ADM <2 years and ≥2 years compared using Mann-Whitney U-test.
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Table 5 Patient demographics and independent
variables, including benzodiazepines and z-hypnotics
n = 1610 Unadjusted odds
ratio (95% CI)
p-value
Mean Age ± SD
(range) years
46 ± 12 (18 to 70) 1.00 (1.00 to 1.01) 0.432
Male (%) 551 (34.2) 1
Female (%) 1059 (65.8) 1.17 (0.93 to 1.46) 0.186
Deprivation (%)
SIMD quintile 1
(least deprived)
93 (5.9) 1
SIMD quintile 2 153 (9.7) 0.92 (0.50 to 1.70) 0.794
SIMD quintile 3 90 (5.7) 1.75 (0.90 to 3.43) 0.101
SIMD quintile 4 264 (16.7) 1.29 (0.73 to 2.28) 0.373
SIMD quintile 5
(most deprived)
985 (62.1) 1.41 (0.82 to 2.44) 0.213
SIMD unknown
(not in mode)
25 (1.6)
†Co-morbidities (%)
0 1028 (63.9) 1
1 415 (25.8) 1.20 (0.93 to 1.55) 0.152
≥2 167 (10.4) 1.12 (0.79 to 1.58) 0.533
Current Smoking
Status (%)
Non-smoker 900 (56.6) 1
Smoker 691 (43.4) 1.16 (0.93 to 1.45) 0.192
Smoking status
unknown
(not in model)
19 (1.2)
SSRI use (%)
ADM for <2 y (%) 1143 (71.0) 1
Same ADM for ≥2 y 467 (29.0) 1.94 (1.53 to 2.47) <0.001
Practice (% practice pop.)
1 82 (5.1) 1
3 242 (15.0) 1.48 (0.77 to 2.83) 0.241
6 201 (12.5) 2.78 (1.49 to 5.18) 0.001
8 322 (20.0) 1.96 (1.07 to 3.58) 0.029
9 181 (11.2) 4.17 (2.22 to 7.81) <0.001
10 302 (18.8) 2.60 (1.42 to 4.78) 0.002
11 280 (17.4) 3.62 (1.98 to 6.66) <0.001
B&Z use (%)
None 1420 (88.2) 1
Long-term B&Z
for ≥8 weeks
190 (11.8) 2.05 (1.47 to 2.86) <0.001
CI: 95% confidence interval. SD: standard deviation. SIMD: Scottish Index
of Multiple Deprivation. SSRI: selective serotonin re-uptake inhibitor.
ADM: antidepressant medicine.
†Co-morbidities: Individuals had one or more of the following: asthma, COPD,
cardiovascular disease, stroke, diabetes mellitus and/or hypertension.
B&Z: bzodiazepine and/or z –hypnotic.
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held: there was no evidence of multi-collinearity (no
variables were highly correlated >0.8), the link test was
correctly specified (hatsq z = 0.87; p = 0.39) and Hosmer
and Lemeshow’s goodness of fit test failed to achieve sig-
nificance (Chi-square (10) = 3.24; p = 0.92).
Discussion
Summary of main findings
Higher SSRI doses for depression treatment were sta-
tistically significantly associated with the following vari-
ables in descending order of magnitude by odds ratios:
individual practice attended, being prescribed the same
SSRI for ≥2 years and living in a more deprived area.
When long-term B&Z prescribing was explored as an ex-
planatory variable in a separate analysis, SSRI doses were
found to be statistically significantly associated with: indi-
vidual practice attended, long-term B&Z prescribing and
being prescribed the same SSRI for ≥2 years.
Strengths and limitations
The use of patient-level data, specifically individuals’
antidepressant dose and indication, enabled this study to
overcome limitations of previous studies [2,15-17,19,39].
By excluding non-mental health and non-depression
SSRI use we identified characteristics associated with in-
dividuals receiving higher SSRI doses for the treatment
of depression only.
Unlike other antidepressants, SSRIs demonstrate a flat
dose response curve for the treatment of depression with
higher than standard doses (>1 DDD) being of question-
able benefit [29-31,36,37]. Therefore the use of logistic
regression enabled the identification of patient-level vari-
ables associated with differences in SSRI standard thera-
peutic doses versus those on higher doses which are of
clinical interest and possibly of more importance in the
long-term use of SSRIs.
However this study has some limitations. The cross sec-
tional nature of the study does not permit any analysis of
dose progression in time from first starting an antidepres-
sant; dose values captured may be discontinued, reduced
or increased soon after data capture. As data capture was
staggered from September 2009 to January 2011 the re-
lease of updated and new guidance may have influenced
prescribing, although the guidance did not advise new
changes in antidepressant doses but further highligh-
ted the non-pharmacological management of depression
[30,40,41], although antidepressant growth has steadily
and consistently continued to increase, on average, by 5%
per annum since 2004/05 with no clear change in trajec-
tory since the introduction of updated and new guidance
[8]. However we cannot rule out that practices at the end
of the data collection period may have changed practice in
response to the updated and new guidance.
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influenced our results were not knowing whether pa-
tients took their medicines as prescribed, however only
those for whom prescriptions for the SSRIs were issued
within the three months prior to data capture were
included, and we knew that patients prescribed the same
SSRI for ≥2 years were issued with regular SSRI prescrip-
tions. Depression severity and specialist mental health re-
view may also have influenced the use higher SSRI dose,
however the majority of patients with depression are diag-
nosed and treated by their GP without seeing psychiatrists
or attending specialist mental health services, and are seen
as having milder depressive symptoms [42]. Patient ethni-
city is known to be associated with lower practice level
antidepressant and B&Z prescribing [43,44] and inclusion
in our analysis would have provided further context to this
study; however, patient-level ethnicity data were unreliably
and inconsistent which precluded their inclusion in this
study.
As this was not a prospective research study, and was
completed as part of NHSGG&C service evaluation and
ongoing commitment to understanding and evaluating
current practice [26], findings may not be generalisable
to other areas. However this study’s findings may be of
interest to others working in similar urban practices with
similar demographics to this population.
Comparison with existing literature
We found that 6.3% of the adult practice population were
prescribed an SSRI; as expected this was lower than pre-
vious UK studies which focused exclusively on SSRI
and non-SSRI prescribing: 6.9% [10], 8.6% [12] and NHS
Scotland’s estimate of 11.3% [8]. The proportion of fe-
males and males prescribed SSRIs of 67.3% and 32.7% re-
spectively is consistent with other studies [8,39], and
87.2% being prescribed an SSRI for depression is slightly
higher than 85.4% previously reported in a general practice
study including all antidepressants [45]. In comparison
28.3% being prescribed the same antidepressant long-term
is lower than previous studies, 47.1% using the same defin-
ition of long-term use [12], and 40.6 to 51.4% [16] and 33
to 55% [10] using slightly different definitions. Differences
may also reflect GPs’ interest in depression management
and optimal care, in managing depression as a long-term
condition, and possibly not reducing review frequency as
patients continue on longer antidepressant courses [45].
Previous studies indicate that individual patient-level
socioeconomic deprivation is significantly associated
with early antidepressant discontinuation [39] whereas
this study identifies higher deprivation as having a small
but significant association with higher prescribed daily
doses.
Complex subjective patient and prescriber factors may
influence the size of a prescribed daily dose. As patientsbecome ‘experts’ in their condition they become more
informed and enabled, making more informed decisions
about medicines; possibly voicing their expectations and
preferences to use higher antidepressant doses [46,47].
Although, prescribers may respond to illness severity,
and perceived safety and better tolerability of SSRIs
[48,49], as well as ‘pushing the dose’ as GPs have also
previously been criticised for prescribing subtherapeutic
doses of antidepressants for the treatment of depression
[11]. However, an inextricable combination of these known,
and other unknown, factors may have contributed to the
average SSRI doses for individual drugs in this study being
up to 25% higher for <2 years use, and up to 42% higher for
those prescribed the same SSRI for ≥2 years, when com-
pared to previous cross sectional studies [11,50,51], and al-
though we acknowledge the dose trajectory limitations of
this study the routine use of such higher doses will further
drive total antidepressant prescription and DDD volumes
as SSRI account for the majority of antidepressants pre-
scribed in Scotland [8].
Unexpectedly, in contrast to practice level studies, pre-
scribed daily dose was not associated with co-morbidity
[19]. This suggests that practices with a higher propor-
tion of patients with long-term illness treat more pa-
tients with antidepressants rather than prescribing higher
doses to fewer patients. This study did not find any associ-
ation between SSRI dose and smoking which is suspected
to influence antidepressant response [22]. However, long-
term B&Z use was associated with higher SSRI doses
which is compatible with previous observations of in-
creased long-term (>4 weeks) B&Z use with SSRIs [35].
Implications for practice and research
The overarching challenge for current and future practice
is continuing support and management for people with
common mental health problems, such as depression
which is relapsing and remitting, and of a long-term na-
ture. Pragmatically, as long-term prescribing increases
[16] and frequency of review decreases with antidepres-
sant duration [45], more consideration should be given
to managing depression as a long-term condition. This
would enable opportunities to review and optimise care to
match individuals’ needs whether that be pharmacological,
non-pharmacological, non-medicalised or a combination
of these [12,52].
In line with current guidance [29-31,40] standard me-
dical texts such as the British National Formulary should
consider including information highlighting differences
in antidepressant dose response effects for the treatment
of depression as, unlike tricyclic antidepressants (TCAs),
SSRIs have traditionally been prescribed at therapeutic
doses [11]. Over the years campaigns [53] and guidelines
[29-31] have advised prescribers to increase antidepres-
sant doses to achieve better drug response and remission
Johnson et al. BMC Family Practice  (2014) 15:210 Page 9 of 11of depressive symptoms. However this advice is appro-
priate for routine use of TCAs and venlafaxine but not
SSRIs, due to their flat dose response curve [29-31,40];
higher doses do not routinely provide better efficacy
[29-31] but increase the risk of adverse effects such as
anxiety and/or insomnia [36,54]. Such adverse effects
may influence combination antidepressant use and/or
concomitant B&Z use [35,55] with regular B&Z use
negatively affecting depression and/or anxiety symp-
toms [23,24] possibly resulting in SSRI doses being
‘pushed’ further. As 1 in 10 patients in the B&Z sub-
group analysis were prescribed long-term B&Zs and an
SSRI, and considering B&Zs negative effects, patients
prescribed such combinations should be considered a
priority for ongoing review and follow up to minimise
inappropriate prescribing, and where possible reduce
and stop B&Z use.
The difference in short-term and long-term doses
raises complex questions such as whether patients are
receiving the most effective drug and dose in line with
guidance [29,30]; what is the potential loss of antide-
pressant efficacy with treatment duration [56,57]
where some patients respond to ‘pushing the dose’
and others dose reduction [56]; whether neuroprogres-
sive changes in depression affect drug response [58],
and the challenge of accurately diagnosing depression
[34,59-61].
Future research should consider prospective longi-
tudinal studies assessing antidepressant response and
outcomes, dose response and changes over treatment
lifetime. Qualitative approaches have a role in exploring
service user expectations of antidepressant treatment
and dose; why GPs ‘push the dose’ and how continuing
care is provided. A prospective comprehensive research
study, including patient-level and practice-level vari-
ables, from a large random sample of general practices
is warranted to enable multi-level modeling and further
contextualise this study's findings.Conclusion
This study has demonstrated that higher SSRI prescribed
daily doses for depression are associated with patients’
general practice attended and being prescribed the same
antidepressant for ≥2 years. As long-term antidepressant
use increases, the use of higher doses may further con-
tribute to prescribing growth. However, the routine use
of such higher SSRI doses for depression is not sup-
ported by current evidence or guidelines. Therefore, in
the short-term, lower prescribing could be achieved via
audit and feedback of practice prescribing patterns [62]
and GP face-to-face reviews of those already on long-
term antidepressants [12] which have both been effective
in reducing costs and prescribing volumes.Additional file
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